Change over period: —
NSE · INDGN
INDGN
-1.7% from the 52-week high · +54.7% above the low
Indegene Ltd provides healthcare solutions through technology-enabled services. The company offers medical communications, commercial analytics, and digital marketing support to global pharmaceutical and biotech clients, helping them optimize patient engagement and market performance.
The short version. INDGN reported revenue of ₹1,122 crore for Sep 2026, up 39.6% from a year earlier. Net profit was ₹112 crore (up 9.8% year on year). Return on equity was 12.8% in Mar 2026.
1 · The price
How has the stock traded?
INDGN trades 1.7% below its 52-week high and 54.7% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹1,122 cr.
Sep 2026 net profit of ₹112 cr.
2.7 pts lower than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1122 | 1063 | 1003 | 942 | 804 | 761 | 756 | 720 |
| Net profit | 112 | 116 | 80 | 103 | 102 | 116 | 118 | 110 |
| Net margin % | 10.0 | 10.9 | 7.9 | 10.9 | 12.7 | 15.3 | 15.6 | 15.2 |
| EPS (₹) | 4.66 | 4.82 | 3.31 | 4.28 | 4.25 | 4.85 | 4.9 | 4.58 |
Annual
| FY2026 | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | 3510 | 2839 | 2590 |
| Net profit | 401 | 407 | 337 |
| Net margin % | 11.4 | 14.3 | 13.0 |
| EPS (₹) | 16.65 | 16.95 | 14.07 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 12.8% in Mar 2026; debt to equity is 0.00.
Profitability · 3 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Return on equity % | 12.8 | 15.6 | 23.6 |
| Return on capital % | 15.4 | 20.3 | 26.3 |
| EBITDA margin % | 18.7 | 21.8 | 21.9 |
| Net margin % | 11.2 | 13.8 | 12.6 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Up 7.37 pts over 8 quarters.
Up 11.84 pts over 8 quarters.
+5 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FII | 5.03 | 5.24 | 10.05 | 11.3 | 11.48 | 10.27 | 9.91 | 12.4 | +7.37 |
| DII | 3.98 | 4.96 | 7.2 | 6.96 | 8.07 | 8.3 | 8.74 | 15.82 | +11.84 |
| Public | 90.99 | 89.8 | 82.75 | 81.74 | 80.45 | 81.44 | 81.34 | 71.77 | -19.22 |
Mutual fund holdings · Oct 2026
46 schemes hold this stock
41 the month before.
- Sundaram Business Cycle Fund2.93% of NAV
- Invesco India Technology Fund2.81% of NAV
- Groww Value Fund2.12% of NAV
- Navi Aggressive Hybrid Fund2.1% of NAV
- Groww Small Cap Fund2.05% of NAV
- Navi Large & Midcap Fund1.77% of NAV
- SBI Innovative Opportunities Fund1.73% of NAV
- quant Small Cap Fund1.58% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for INDGN are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Healthcare Services stocks
Quick answers
Common questions about INDGN
What is the INDGN share price?
INDGN (INDGN) last closed at ₹645.40, down 1.46% on the day. Its 52-week range is ₹423.50 to ₹666.20.
What is the market cap of INDGN?
INDGN has a market capitalisation of about ₹15,778 crore. Its price-to-earnings ratio is 38.5.
How are INDGN's latest results?
INDGN reported revenue of ₹1,122 crore for Sep 2026, up 39.6% from a year earlier. Net profit was ₹112 crore (up 9.8% year on year). Return on equity was 12.8% in Mar 2026.
Who owns INDGN?
As of Sep 2026, shareholding was: FII 12.4%, DII 15.82%, Public 71.77%.
How many mutual funds hold INDGN?
46 mutual fund schemes held INDGN in October 2026. That compares with 41 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 13 Jun 2025 · Final Dividend - Rs. 2
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.